President John Mahama (right) and officials cutting a ribbon to commission the DNA Laboratory
President John Mahama (right) and officials cutting a ribbon to commission the DNA Laboratory

President commissions DNA Lab, vaccine research facility at Noguchi

President John Dramani Mahama has emphasised that Ghana will continue to make investments in its health sector to ensure that it no longer depends on foreign countries for critical scientific services.

Commissioning two landmark facilities at the Noguchi Memorial Institute for Medical Research (NMIMR), President Mahama described the event as "a day of pride" for the nation and a significant milestone in Ghana's quest for health sovereignty and scientific self-reliance.

The facilities, a National Human Identification Laboratory, commonly known as the DNA Lab, and a state-of-the-art Vaccine Research Facility comprising mRNA and protein laboratories, were unveiled last Wednesday at the University of Ghana, Legon.

No more reliance

The establishment of the DNA Laboratory follows the tragic events of August 6, when the nation was forced to send tissue samples from accident victims to South Africa for analysis, leaving grieving families to wait "several nerve-racking days" for results.

"It was a day of shame for Ghana that we couldn't carry out our own DNA analysis in-country.

That will be a thing of the past," the President declared. "I am proud now that we have a world-class facility that will strengthen our forensic and public health systems."


President Mahama indicated that the facility would not only provide answers to families in times of tragedy, but also assist in forensic investigations, including cases of rape, murder and other crimes, thereby improving national security.

It would also be instrumental in settling paternity disputes, inheritance matters and travel-related documentation issues.

"Behind every request for identification is a family that is waiting anxiously for news.

For that family, the wait can deepen the pain of loss and delay the chance to lay a loved one to rest," he said, urging agencies relying on the laboratory to prioritise timely communication with affected families.

Self-Sufficiency

Touching on the vaccine research laboratories, the President said the COVID-19 pandemic had exposed the vulnerabilities of African countries in accessing critical medical supplies.

He noted that beyond COVID-19, the sub-region continued to face recurring threats from infectious diseases such as M-pox, Lassa fever, Ebola and Marburg virus, stressing the need for preparedness.

"Preparedness requires foresight, investment and the courage to build capacity before a crisis strikes," he said.

The President revealed that Ghana is now one of only five African countries using innovative mRNA technology to research and develop new vaccines, positioning the nation as a leader in the continent's scientific advancement.

The President used the occasion to urge Ghanaians to embrace clinical trials, dispelling misconceptions that had previously derailed research efforts.

He recalled how scaremongering during the Ebola outbreak forced researchers, including the late Professor Fred Binka, to relocate a proposed clinical trial from the Volta Region to East Africa.

"We develop vaccines and an essential part of developing vaccines is clinical trials...


Nobody will do the clinical trials for us to develop vaccines in our country. And so that is my message to you," he emphasised.

President Mahama expressed optimism that the facilities would inspire young scientists to build careers in Ghana and contribute to global health research, saying, “I hope the young scientists and students here today will see in these laboratories a place to build a career in Ghana.”

Five scientists recognised

The President acknowledged five Ghanaian scientists who have been trained in Brussels and Accra to lead the mRNA technology effort, describing them as pioneers of a "training of trainers" initiative.

They are Prof. Linda Eva Amoah, Prof. Peter Kojo Quashie, Prof. Augustina Angelina Sylverken, Dr Ruben Jani-Ayuvo and Dr Festus Kojo Acquah.

The scientists were drawn from NMIMR, the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) and the University of Health and Allied Sciences (UHAS).